Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kanghui Bullish On Joint Implants Despite Looming Price Cuts; Mindray Undercutting U.S. Competition: China Earnings Roundup (Part 4)

This article was originally published in PharmAsia News

Executive Summary

Regulatory headwinds and price cuts led to a massive slowdown in China’s pharmaceutical industry in Q3, but China’s device makers are still enjoying fast growth.

You may also be interested in...

Kanghui: A New Strategic Opens The Door To Orthopedics In China

China Kanghui has emerged as one of the leaders in China’s orthopedics industry, building a business first on trauma and, more recently, spine. Now, with a pending move into reconstruction, the company is looking to other emerging markets, and eventually the US and Europe.

China's Pilot DRG Reimbursement Systems Indicate Substantial Changes To Hospital Prescription Habits

SHANGHAI - China is experimenting with pilot reimbursement programs that rely on diagnosis related groups (DRG) in cities across the country, looking for ways to reduce medical expenses

China's Top Device Maker Mindray Enters Critical Care Market; Sees Boosts From Color Ultrasound Devices

Despite a negative impact from political unrest in the Middle East, China's leading medical device maker Mindray Medical International is steaming ahead with solid first quarter growth in both international and Chinese domestic markets. That growth was driven largely by a continued stronghold in its low- to mid-end device market, as well as an emerging footprint in the lucrative high-end segment with its color ultrasound devices

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts